Our strategy was pretreatment by Rad51-inhibitory substances by intravenous low-dose gemcitabine followed by arterial administration of antineoplastic agents causing DNA, DSB, or DNA crosslink, which might be more beneficial for patients with locally advanced pancreatic cancers than other treatments previously reported. This evidence concerns the gene RAD51 and pancreatic neoplasm.